Therapeutics/Diagnostics News

A familial risk score comprised of age, obesity, type 2 diabetes and family history of nonalcoholic fatty liver disease accurately identified advanced fibrosis among first-degree relatives, according to researchers.

Among patients with ulcerative colitis, delayed Stelara responders had greater inflammatory burden at baseline compared with early responders, yet similar 1-year clinical remission outcomes, researchers reported.

In two phase 3 trials, mirikizumab induced and maintained remission at a higher rate compared with placebo among patients with moderate to severely active ulcerative colitis, according to data in The New England Journal of Medicine.

Bulevirtide was safe and increased the proportion of patients with undetectable hepatitis D virus RNA among those in both the 2 mg and 10 mg dosage groups, according to data published in The New England Journal of Medicine.

A novel scoring system could aid clinicians by predicting the risk for 30-day reintervention among patients who underwent endoscopic sleeve gastroplasty, according to data published in Gastrointestinal Endoscopy.

In a Healio video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on primary biliary cholangitis presented at EASL Congress, including risk factors for disease progression and seladelpar for treatment of pruritus.

Mycophenolate mofetil was superior to azathioprine in achieving biochemical remission in treatment-naive patients with autoimmune hepatitis who were also treated with prednisolone, according to data presented at EASL Congress.

Computer-aided detection in colonoscopy had a “positive effect” on adenoma detection rate, mean number of adenomas per colonoscopy and polyp detection rate and should be considered when performing routine colonoscopy, researchers reported.

Treatment with lonafarnib boosted with ritonavir, with or without peginterferon alfa, resulted in significant virological and biochemical response in patients with chronic hepatitis D virus infection, according to data presented.

Fecal microbiota transplantation improved gut barrier function, mucosal immunity and ammonia metabolism in patients with cirrhosis, which could reduce hepatic encephalopathy and other infections, according to data from the PROFIT trial.